Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.35 |
| ▸ | USP2 | O75604 | 6/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19905405 | 0.97 | FEN1 (0.36) | FFAR4CSF1RCYP1A2CYP3A4CLK4 | |
| SCHEMBL22838609 | 0.91 | CYP1A2 (0.36) | CSF1RCYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL19905429 | 0.91 | CYP1A2 (0.35) | CYP1A2CYP3A4CLK4USP2CYP2C19 | |
| SCHEMBL19355618 | 0.90 | CYP1A2 (0.37) | CYP1A2CYP3A4CLK4USP2CYP2C19 | |
| SCHEMBL19905355 | 0.88 | CYP1A2 (0.36) | CSF1RCYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL19355139 | 0.88 | PIP5K1C (0.38) | CYP1A2CYP3A4CLK4USP2CYP2C19 | |
| SCHEMBL19905266 | 0.88 | PRKDC (0.37) | CYP1A2CYP3A4CLK4USP2CYP2C19 | |
| SCHEMBL19355152 | 0.88 | KDM4E (0.37) | CYP1A2CYP3A4CLK4USP2CYP2C19 | |
| SCHEMBL22838686 | 0.88 | PTGES (0.36) | FFAR4CYP1A2CYP3A4CLK4USP2 | |
| SCHEMBL19355619 | 0.87 | CYP1A2 (0.40) | CYP1A2CYP3A4CLK4USP2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057959-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170258789-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258789-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | FFAR4 4806/4885CSF1R 3986/4885CYP1A2 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.